<DOC>
	<DOCNO>NCT01344031</DOCNO>
	<brief_summary>This phase I trial study side effect best dose MK 2206 ( Akt inhibitor MK2206 ) give anastrozole , fulvestrant , anastrozole fulvestrant treat postmenopausal woman breast cancer spread part body . Estrogen cause growth breast cancer cell . Hormone therapy use anastrozole fulvestrant may fight breast cancer lower amount estrogen body make . Akt inhibitor MK2206 may stop growth tumor cell block enzymes need cell growth . Giving Akt inhibitor MK2206 together anastrozole , fulvestrant , anastrozole fulvestrant may kill tumor cell .</brief_summary>
	<brief_title>MK2206 Combination With Anastrozole , Fulvestrant , Anastrozole Fulvestrant Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) MK-2206 combination anastrozole base toxicity observe cycle 1 therapy . ( Phase IA ) II . To evaluate tolerability prolong administration ( 3 month ) MK-2206 combination anastrozole MTD define Phase IA . ( Phase IB ) III . To determine recommended phase II treatment dosing ( RPTD ) MK-2206 combination anastrozole base toxicity observe prolonged drug administration . ( Phase IB ) IV . To determine tolerability fulvestrant ( Arm C ) , fulvestrant plus anastrozole ( Arm D ) , respectively , combination MK-2206 ( RPTD define Phase 1B ) . ( Arms C D ) V. To determine recommended phase II treatment dose ( RPTD ) fulvestrant ( Arm C ) fulvestrant plus anastrozole ( Arm D ) , respectively , combination MK-2206 base toxicity observe prolonged drug administration ( 3 month ) . ( Arms C D ) VI . To evaluate toxicity profile MK-2206 combination fulvestrant ( Arm C ) fulvestrant plus anastrozole ( Arm D ) , respectively , prolong drug administration . ( Arms C D ) SECONDARY OBJECTIVES : I . To evaluate toxicity profile MK-2206 combination anastrozole , fulvestrant , anastrozole plus fulvestrant . II . To evaluate clinical benefit rate ( CBR : complete response [ CR ] +partial response [ PR ] +stable disease [ SD ] &gt; 6 month ) , response rate ( CR+PR ) , percent patient progression free 6 month treatment MK-2206 combination anastrozole , fulvestrant anastrozole plus fulvestrant patient estrogen receptor positive ( ER+ ) metastatic breast cancer . III . To examine serum level estradiol prior follow 1 cycle MK-2206 therapy . TERTIARY OBJECTIVES : I . To examine baseline tumor specimen alteration phosphatidylinositol 3 kinase ( PI3K ) pathway gene explore relationship treatment response . II . To evaluate effect MK-2206 tumor cell v-akt murine thymoma viral oncogene homolog 1 ( AKT ) signaling , proliferation , apoptosis use serially collect tumor sample available case . III . To examine change tumor cell glucose uptake positron emission tomography ( PET ) 2- [ 18F ] fluoro-2-deoxy-D-glucose ( FDG ) baseline 24 h post day 1 MK-2206 . ( Phase IA ) IV . To examine phosphatidylinositol-4,5-bisphosphate 3-kinase , catalytic subunit alpha ( PIK3CA ) mutation status circulate deoxyribonucleic acid ( DNA ) baseline follow study therapy correlate tumor tissue PIK3CA status treatment response . OUTLINE : This phase I , dose-escalation study Akt inhibitor MK2206 follow recommended phase II dose ( RPTD ) study . Patients assign treatment arm currently open . ARM A : Patients receive anastrozole orally ( PO ) day 1-28 . Beginning course 2 , patient receive Akt inhibitor MK-2206 PO day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM B : The RPTD Akt inhibitor MK2206 anastrozole determine 3 course , administer Arm A . ARM C : Patients receive Akt inhibitor MK2206 PO day 1 , 8 , 15 , 22 , fulvestrant intramuscularly ( IM ) day 1 day 15 course 1 day 1 course subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM D : Patients receive Akt inhibitor MK2206 PO Arm A , anastrozole PO day 1-28 fulvestrant IM day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . NOTE : As 8/19/2015 , Arms , patient longer receive Akt inhibitor MK2206 . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Patients must histologically cytologically confirm invasive breast cancer metastatic stage IV recurrent metastatic ( histologic/cytologic confirmation recurrence prefer , require ) Either primary metastatic tumor must positive estrogenreceptor ( &gt; 1 % tumor cell stain immunohistochemistry Allred score &gt; = 3 immunohistochemistry ) Patient must measurable nonmeasurable lesion ( define Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 criterion ) Note : eligible FDG PET image study Phase IA , presence measurable lesion least 1.5 cm presence bone lesion require Patients may undergo number prior line chemotherapy endocrine regimen must history disease progression anastrozole ( Phase IA Phase IB ) , fulvestrant ( Arm C ) , anastrozole fulvestrant ( Arm D ) Phase IA IB : Currently treat anastrozole evidence disease progression OR Currently treat letrozole exemestane evidence disease progression willing switch anastrozole study enrollment OR Considering switch anastrozole due disease progression recent anticancer therapy Arm C : Currently treat fulvestrant evidence disease progression OR Considering switch fulvestrant due disease progression recent anticancer therapy Arm D : Currently treat either anastrozole fulvestrant evidence disease progression OR Currently treat letrozole exemestane evidence disease progression willing switch anastrozole study enrollment Considering switch anastrozole fulvestrant due disease progression recent anticancer therapy Patients must postmenopausal woman define one following : Women &gt; 60 year Women = &lt; 60 year spontaneous cessation menses &gt; 12 month prior registration Women = &lt; 60 year cessation menses duration &lt; 12 month secondary hysterectomy AND follicle stimulate hormone ( FSH ) level postmenopausal range accord institutional standard ( &gt; 34.4 IU/L institutional range available ) prior registration Women = &lt; 60 year hormonal replacement therapy discontinue hormonal therapy AND FSH level postmenopausal range accord institutional standard ( &gt; 34.4 IU/L institutional range available ) prior registration Status post bilateral surgical oophorectomy Premenopausal woman gonadotropinreleasing hormone ( GnRH ) analog Patients must life expectancy great 4 month Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Leukocytes &gt; = 3,000/mcL Absolute neutrophil count ( ANC ) &gt; = 1,500/mcL Platelet count &gt; = 100,000/mcL Total bilirubin institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal Creatinine institutional upper limit normal OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal If patient diabetes mellitus , fast glucose must = &lt; 120 mg/dL hemoglobin ( Hb ) A1c = &lt; 8 % Women childbearing potential must use two form contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , patient inform treat physician immediately Patients know brain metastasis eligible stable ( evidence local progression ) &gt; = 3 month local therapy steroid Patients eligible study may also eligible participate National Cancer Institute ( NCI ) Protocol 9167 , title `` Positron Emission Tomography ( PET ) 18FFluoroestradiol ( FES ) Predictor Response Patients Breast Cancer Scheduled Be Treated MK2206 Combination Either Aromatase Inhibitor Fulvestrant NCI Protocol 8762 , '' case FESPET Protocol 9167 perform minimum 48 hour maximum 30 day first dose MK2206 ; addition , FESrelated side effect must resolve first dose MK2206 Patients must ability understand willingness sign write informed consent document Patients may chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study ; patient must recover adverse event due agent administer 4 week earlier Patients may receive investigational agent Patients may history allergic reaction attribute compound similar chemical biologic composition MK2206 agent use study Patients receive medication substance strong inhibitor inducer cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP 450 3A4 ) ineligible Note : one week washout period require patient previously take strong inhibitor inducer CYP450 3A4 ; patient currently take moderate inhibitor inducer CYP450 3A4 encourage switch medication interact CYP450 3A4 Patients diabetes risk hyperglycemia exclude trial MK2206 , hyperglycemia well controlled oral agent patient enters trial ( i.e . HbA1c = &lt; 8 % fast glucose = &lt; 120 mg/dL ) Cardiovascular : baseline QT Fridericia formula ( QTcF ) &gt; 450 msec ( male ) QTcF &gt; 470 msec ( female ) exclude patient entry study Patients may uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant nursing patient exclude study Patients know human immunodeficiency virus ( HIV ) positive status exclude study Patients may disease progression anastrozole ( Phase IA Phase IB ) , fulvestrant ( Arm C ) , anastrozole fulvestrant ( Arm D ) either neoadjuvant , adjuvant ( defined disease recurrence identify within 6 month adjuvant discontinuation ) , metastatic setting Patients may grade 3 intolerable grade 2 adverse event runin aromatase inhibitor ( AI ) fulvestrant therapy prior start MK2206 Patients may prior therapy AKT inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>